Top Markets
#1 Islamic Coin Islamic Coin +155.98%
#2 Siren Siren +37.73%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.35%
#4 OpenEden OpenEden +20.76%
#5 Cysic Cysic +18.55%
#6 Verus Coin Verus Coin +17.78%
#7 Ocean Protocol Ocean Protocol +15.78%
#8 RedStone RedStone +14.31%
#9 Arowana Arowana +13.93%
#10 Perle Perle +13.71%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Intensity Therapeutics, Inc. Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc.

INTS
Rank in Stocks #32091
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical... Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Share Price
$4.12
Last synced: 2026-08-17
Market Cap
$11.14M
Change (1 day)
4.04%
Change (1 year)
-45.79%
Country
US
Trade Intensity Therapeutics, Inc. (INTS)

Category

Healthcare
Number of shares outstanding for Intensity Therapeutics, Inc. (INTS)
Number of shares outstanding as of August 2026: 0
According to Intensity Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Intensity Therapeutics, Inc. (INTS) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR